StreetInsider.com News Articles

Raymond James cuts Cigna to Outperform on lack of near-term catalysts

Mon, 03 Aug 2026 10:54:15 -0400

Investing.com -- Raymond James downgraded Cigna Group to Outperform from Strong Buy and lowered its price target to $320 from $350, saying the health insurer's valuation remains attractive but near-term catalysts are lacking as growth moderates and its pharmacy benefit management (PBM) business faces ongoing headwinds.

The brokerage said Cigna operates in a mature market with slower growth than other names under its coverage and expects continued investments in the PBM transition, combined with limited customer growth, to weigh on earnings momentum over the medium term. While its specialty pharmacy business is offsetting some of the weakness,

Raymond James Downgrades CIGNA (CI) to Outperform

Mon, 03 Aug 2026 07:20:19 -0400

Raymond James analyst John Ransom downgraded CIGNA (NYSE: CI) from Strong Buy to Outperform with a price target of $320.00 (from $350.00).

The analyst comments "We are downgrading our rating on CI to Outperform while lowering our price target to $320 (~8.5x 2028E EPS). The reasons for the downgrade are as follows: 1) We view CI as a slower growth name operating in a mature market, and see more attractive upside at other names in our coverage. 2) We don’t see a clear catalyst over the next 6-12 months that would support our prior Strong Buy rating. And 3) the PBM

Raymond James Downgrades CIGNA (CI) to Outperform

Mon, 03 Aug 2026 07:20:19 -0400

Raymond James analyst John Ransom downgraded CIGNA (NYSE: CI) from Strong Buy to Outperform with a price target of $320.00 (from $350.00).

CIGNA (CI) PT Raised to $307 at Wells Fargo

Fri, 31 Jul 2026 08:35:50 -0400

Wells Fargo analyst Stephen Baxter raised the price target on CIGNA (NYSE: CI) to $307.00 (from $305.00) while maintaining a Equal Weight rating.

CIGNA (CI) PT Raised to $361 at Guggenheim

Fri, 31 Jul 2026 07:47:09 -0400

(Updated - July 31, 2026 7:47 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on CIGNA (NYSE: CI) to $361.00 (from $338.00) while maintaining a Buy rating.

The analyst commented: "CI reported 2Q26 EPS upside from another quarter of Specialty & Care strength (accelerated biosimilars + generic conversions) combined with favorable cost trend development within Healthcare (outpatient). As a partial offset, CI’s PBM realized slight headwinds from GLP-1 moderation + the loss of related generic conversion economics, even though the latter still develops as a positive for the overall Evernorth franchise. Net-net, investors likely wanted to see more pull-through to

CIGNA (CI) PT Raised to $361 at Guggenheim

Fri, 31 Jul 2026 07:47:09 -0400

(Updated - July 31, 2026 7:47 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on CIGNA (NYSE: CI) to $361.00 (from $338.00) while maintaining a Buy rating.

CIGNA (CI) PT Raised to $362 at Baird

Fri, 31 Jul 2026 07:18:58 -0400

Baird analyst Michael Ha raised the price target on CIGNA (NYSE: CI) to $362.00 (from $337.00) while maintaining a Outperform rating.

CIGNA (CI) PT Raised to $310 at Barclays

Fri, 31 Jul 2026 06:12:01 -0400

Barclays analyst Andrew Mok raised the price target on CIGNA (NYSE: CI) to $310.00 (from $304.00) while maintaining a Equalweight rating.

Form 10-Q Cigna Group For: Jun 30

Thu, 30 Jul 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260730/26841922.html

Form 10-Q Cigna Group For: Jun 30

Thu, 30 Jul 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260730/26841922.html

Cigna beats Q2 estimates, lifts earnings guidance

Thu, 30 Jul 2026 06:50:38 -0400

Investing.com -- The Cigna Group (NYSE:CI) reported second-quarter earnings and revenue that exceeded analyst expectations, while raising its full-year outlook, though shares fell 1% premarket following the announcement.

The health company posted adjusted earnings of $7.78 per share for the second quarter, beating the analyst consensus of $7.59 by $0.19. Revenue increased 7% YoY to $71.7 billion, surpassing the $70.18 billion estimate.

The company raised its full-year 2026 adjusted earnings outlook to at least $30.45 per share, up $0.10 from its prior projection and slightly above the analyst consensus of $30.41.

The revenue growth was driven by increases in both the

Cigna beats Q2 estimates, lifts earnings guidance

Thu, 30 Jul 2026 06:50:38 -0400

The company raised its full-year 2026 adjusted earnings outlook to at least $30.45 per share, up $0.10 from its prior projection and slightly above the analyst consensus of $30.41.

The revenue growth was driven by increases in both the

Form 8-K Cigna Group For: Jul 30

Thu, 30 Jul 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20260730/26838024.html

Form 8-K Cigna Group For: Jul 30

Thu, 30 Jul 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20260730/26838024.html

Cigna Corp. (CI) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance

Thu, 30 Jul 2026 06:04:07 -0400

Cigna Corp. (NYSE: CI) reported Q2 EPS of $7.78, $0.19 better than the analyst estimate of $7.59. Revenue for the quarter came in at $71.7 billion versus the consensus estimate of $70.18 billion.

GUIDANCE:

Cigna Corp. sees FY2026 EPS of $30.45, versus the consensus of $30.41.